https://www.sec.gov/ix?doc=/Archives/edgar/data/0000879169/000087916926000013/incy-20260227.htm
On February 27, 2026, The FDA Issued Complete Response Letter For The Supplemental Biologics License Application For Zynyz; CRL Cites Catalent Indiana Regulatory Compliance As Sole Approvability Issue
Login to comment